


Attorney Docket No.: DEX-0293  
Inventors: Salceda et al.  
Serial No.: 09/995,494  
Filing Date: November 27, 2001  
Page 3

claims 14 and 15 have been amended to depend from claims 1 and 11. No new matter has been added by this amendment. Entry of this amendment is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Respectfully submitted,

  
Kathleen A. Tyrrell  
Registration No. 38,350

Date: February 20, 2002

LICATA & TYRRELL P.C.  
66 E. Main Street  
Marlton, NJ 08053  
856-810-1515

Attorney Docket No.: DEX-0293  
Inventors: Salceda et al.  
Serial No.: 09/995,494  
Filing Date: November 27, 2001  
Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Please amend claims 14 and 15 as follows:

14. (amended) A method for diagnosing and monitoring the presence and metastases of prostate cancer in a patient, comprising the steps of:

(a) determining an amount of the nucleic acid molecule of claim 1 or a polypeptide of claim 6 or 11 in a sample of a patient; and

(b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the prostate specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of prostate cancer.

15 (amended) A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence the nucleic acid molecule of claim 1 or a polypeptide of claim 6 or 11 in a sample of a patient.